Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/132486
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorVeselka, J.en
dc.contributor.authorLiebregts, M.en
dc.contributor.authorCooper, R.en
dc.contributor.authorFaber, L.en
dc.contributor.authorJanuska, J.en
dc.contributor.authorKashtanov, M.en
dc.contributor.authorTesarkova, K. H.en
dc.contributor.authorHansen, P. R.en
dc.contributor.authorSeggewiss, H.en
dc.contributor.authorShloydo, E.en
dc.contributor.authorPopov, K.en
dc.contributor.authorHansvenclova, E.en
dc.contributor.authorBonaventura, J.en
dc.contributor.authorBerg, J. T.en
dc.contributor.authorStables, R. H.en
dc.contributor.authorPolakova, E.en
dc.date.accessioned2024-04-22T15:53:44Z-
dc.date.available2024-04-22T15:53:44Z-
dc.date.issued2022-
dc.identifier.citationVeselka, J, Liebregts, M, Cooper, R, Faber, L, Januska, J, Kashtanov, M, Tesarkova, KH, Hansen, PR, Seggewiss, H, Shloydo, E, Popov, K, Hansvenclova, E, Bonaventura, J, Berg, JT, Stables, RH & Polakova, E 2022, 'Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation', JACC: Cardiovascular Interventions, Том. 15, № 19, стр. 1910-1917. https://doi.org/10.1016/j.jcin.2022.06.034harvard_pure
dc.identifier.citationVeselka, J., Liebregts, M., Cooper, R., Faber, L., Januska, J., Kashtanov, M., Tesarkova, K. H., Hansen, P. R., Seggewiss, H., Shloydo, E., Popov, K., Hansvenclova, E., Bonaventura, J., Berg, J. T., Stables, R. H., & Polakova, E. (2022). Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation. JACC: Cardiovascular Interventions, 15(19), 1910-1917. https://doi.org/10.1016/j.jcin.2022.06.034apa_pure
dc.identifier.issn1936-8798
dc.identifier.otherFinal2
dc.identifier.otherAll Open Access; Bronze Open Access3
dc.identifier.otherhttps://doi.org/10.1016/j.jcin.2022.06.0341
dc.identifier.otherhttps://doi.org/10.1016/j.jcin.2022.06.034pdf
dc.identifier.urihttp://elar.urfu.ru/handle/10995/132486-
dc.description.abstractBackground: Atrioventricular block is a frequent major complication after alcohol septal ablation (ASA). Objectives: The aim of this study was to evaluate the outcomes of patients with implanted permanent pacemaker (PPM) related to a high-grade atrioventricular block after ASA for hypertrophic obstructive cardiomyopathy. Methods: We used a multinational registry (the Euro-ASA registry) to evaluate the outcome of patients with PPM after ASA. Results: A total of 1,814 patients were enrolled and followed up for 5.0 ± 4.3 years (median = 4.0 years). A total of 170 (9.4%) patients underwent PPM implantation during the first 30 days after ASA. Using propensity score matching, 139 pairs (n = 278) constituted the matched PPM and non-PPM groups. Between the matched groups, there were no long-term differences in New York Heart Association functional class (1.5 ± 0.7 vs 1.5 ± 0.9, P = 0.99) and survival (log-rank P = 0.47). Patients in the matched PPM group had lower long-term left ventricular (LV) outflow gradient (12 ± 12 mm Hg vs 17 ± 19 mm Hg, P < 0.01), more pronounced LV outflow gradient decrease (81% ± 17% vs 72% ± 35%, P < 0.01), and lower LV ejection fraction (64% ± 8% vs 66% ± 8%, P = 0.02) and were less likely to undergo reintervention (re-ASA or myectomy) (log-rank P = 0.02). Conclusions: Patients with hypertrophic obstructive cardiomyopathy treated with ASA have a 9% probability of PPM implantation within 30 days after ASA. In long-term follow-up, patients with PPM had similar long-term survival and New York Heart Association functional class but lower LV outflow gradient, a more pronounced LV outflow gradient decrease, a lower LV ejection fraction, and a lower likelihood of reintervention compared with patients without PPM. © 2022 American College of Cardiology Foundationen
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.publisherElsevier Inc.en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.rightspublisher-specific-oaother
dc.sourceJACC: Cardiovascular Interventions2
dc.sourceJACC: Cardiovascular Interventionsen
dc.subjectALCOHOL SEPTAL ABLATIONen
dc.subjectPERMANENT PACEMAKERen
dc.subjectPROGNOSISen
dc.subjectABLATION TECHNIQUESen
dc.subjectATRIOVENTRICULAR BLOCKen
dc.subjectCARDIOMYOPATHY, HYPERTROPHICen
dc.subjectETHANOLen
dc.subjectHEART SEPTUMen
dc.subjectHUMANSen
dc.subjectPACEMAKER, ARTIFICIALen
dc.subjectRETROSPECTIVE STUDIESen
dc.subjectTREATMENT OUTCOMEen
dc.subjectALCOHOLen
dc.subjectADULTen
dc.subjectALCOHOL SEPTAL ABLATIONen
dc.subjectALL CAUSE MORTALITYen
dc.subjectARTICLEen
dc.subjectATRIOVENTRICULAR BLOCKen
dc.subjectCLINICAL EXAMINATIONen
dc.subjectCOHORT ANALYSISen
dc.subjectCONTROLLED STUDYen
dc.subjectFEMALEen
dc.subjectFOLLOW UPen
dc.subjectHEART BUNDLE BRANCH BLOCKen
dc.subjectHEART LEFT VENTRICLE EJECTION FRACTIONen
dc.subjectHUMANen
dc.subjectHYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHYen
dc.subjectINTERVENTRICULAR SEPTUMen
dc.subjectMAJOR CLINICAL STUDYen
dc.subjectMALEen
dc.subjectMIDDLE AGEDen
dc.subjectMUSCLE RESECTIONen
dc.subjectNEW YORK HEART ASSOCIATION CLASSen
dc.subjectOUTCOME ASSESSMENTen
dc.subjectPACEMAKER IMPLANTATIONen
dc.subjectPROPENSITY SCOREen
dc.subjectSHARED DECISION MAKINGen
dc.subjectSUDDEN CARDIAC DEATHen
dc.subjectABLATION THERAPYen
dc.subjectADVERSE EVENTen
dc.subjectARTIFICIAL HEART PACEMAKERen
dc.subjectATRIOVENTRICULAR BLOCKen
dc.subjectDIAGNOSTIC IMAGINGen
dc.subjectHEART SEPTUMen
dc.subjectHYPERTROPHIC CARDIOMYOPATHYen
dc.subjectRETROSPECTIVE STUDYen
dc.subjectTREATMENT OUTCOMEen
dc.titleOutcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablationen
dc.typeArticleen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.1016/j.jcin.2022.06.034-
dc.identifier.scopus85138367372-
local.contributor.employeeVeselka J., Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republicen
local.contributor.employeeLiebregts M., Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlandsen
local.contributor.employeeCooper R., Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdomen
local.contributor.employeeFaber L., Ruhr-University Bochum, Bochum, Germanyen
local.contributor.employeeJanuska J., Cardiocentre Podlesi, Trinec, Czech Republicen
local.contributor.employeeKashtanov M., Department of Endovascular Therapy, Sverdlovsk Regional Hospital No. 1 and Ural Federal University, Yekaterinburg, Russian Federationen
local.contributor.employeeTesarkova K.H., Department of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republicen
local.contributor.employeeHansen P.R., Department of Cardiology, Herlev and Gentofte Hospital, Hellerup, Denmarken
local.contributor.employeeSeggewiss H., Comprehensive Heart Failure Centre, University Clinic Wurzburg, Wurzburg, Germanyen
local.contributor.employeeShloydo E., Department of Cardiology, City Hospital No. 2, Saint-Petersburg, Russian Federationen
local.contributor.employeePopov K., Department of Cardiology, City Hospital No. 2, Saint-Petersburg, Russian Federationen
local.contributor.employeeHansvenclova E., Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republicen
local.contributor.employeeBonaventura J., Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republicen
local.contributor.employeeBerg J.T., Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlandsen
local.contributor.employeeStables R.H., Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdomen
local.contributor.employeePolakova E., Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republicen
local.description.firstpage1910
local.description.lastpage1917
local.issue19
local.volume15
dc.identifier.wos000879070600005-
local.contributor.departmentDepartment of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republicen
local.contributor.departmentDepartment of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlandsen
local.contributor.departmentInstitute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdomen
local.contributor.departmentRuhr-University Bochum, Bochum, Germanyen
local.contributor.departmentCardiocentre Podlesi, Trinec, Czech Republicen
local.contributor.departmentDepartment of Endovascular Therapy, Sverdlovsk Regional Hospital No. 1 and Ural Federal University, Yekaterinburg, Russian Federationen
local.contributor.departmentDepartment of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republicen
local.contributor.departmentDepartment of Cardiology, Herlev and Gentofte Hospital, Hellerup, Denmarken
local.contributor.departmentComprehensive Heart Failure Centre, University Clinic Wurzburg, Wurzburg, Germanyen
local.contributor.departmentDepartment of Cardiology, City Hospital No. 2, Saint-Petersburg, Russian Federationen
local.identifier.puref36e2b64-320b-4856-a0a9-7b2afe3189f3uuid
local.identifier.pure30981587-
local.identifier.eid2-s2.0-85138367372-
local.identifier.wosWOS:000879070600005-
local.identifier.pmid36202559
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85138367372.pdf543,51 kBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.